Search
Now showing items 1-1 of 1
Article
A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
(2016-03-18)
Background Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the Euro pean Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever ...